Cell No. : Cell Name
RCB0439 : LC-1F
update : 2022/03/15
|
| Comment | Lung Cancer-1/squamous, floating variant, the same patient as RCB0455 LC-1/sq. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Itoh, Hiroshi
|
| Originator |
Kataoka, Hiroaki
|
| Year of deposit |
1989
|
| Original cell |
LC-1/sq
|
| Animal |
human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
69 years
|
| Tissue |
lung
|
| Classification |
cancer
|
| Year of origin |
1986
|
| History |
H. Kataoka
|
| Memo_1 |
Mycoplasma was eliminated with MC-210.
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_1372
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Medium and additives |
|
(HamF12 : RPMI1640 = 1 : 1) + 25mM HEPES + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
| SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
73-181(50) : /83(5),84(1),85(11),86(5),87(3),88(2)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
5
|
| User's Publication |
|
13332
Hase H, Aoki M, Matsumoto K, Nakai S, Nagata T, Takeda A, Ueda K, Minami K, Kitae K, Jingushi K, Ueda Y, Yamamoto M, Furukawa T, Sato M, Tsujikawa K.
Cancer type‑SLCO1B3 promotes epithelial‑mesenchymal transition resulting in the tumour progression of non‑small cell lung cancer.
Oncol Rep
2021
PubMed ID: 33155667
|
|
13773
Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M.
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites
Cancer Sci
2020
111(2):667-678
PubMed ID: 31828882
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
|
|
3338
Seike, Masahiro, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Gemma, Akihiko, Kudoh, Shoji, Hirohashi, Setsuo
Proteomic signature of human cancer cells.
Proteomics
2004
4:2776-88
PubMed ID: 15352251
|
|
3134
Yoshimasu, T. et al
Integrins α2β1,α5β1 and αvβ5 are related to tumor growth and metastasis of non-small cell cancer
Japanese Journal of Lung Cancer
2001
41:111-115
|
Back
Top
CELL BANK Website
